Triclinic Labs is a premier contract research organization focused on solid-state chemical development and comprehensive materials analysis for pharmaceutical, medical device, and fine-chemical clients. Leveraging decades of experience, the company excels in polymorph and salt, form screening and selection, cocrystal screening and formulation, and amorphous material development, as well as crystallization method optimization and particle/habit engineering.
Their state-of-the-art analytical chemistry services encompass X-ray powder diffraction (XRPD), Electron and single crystal diffraction, thermal analysis (TGA/DSC), spectroscopy (Raman, FT-IR, solid-state NMR), chromatography (LC/GC), microscopy (optical, electron, high-speed), Coupled techniques (Mass spectrometry with LC and GC), elemental analysis (EDX, ICP-MS), water content determination (KF, DVS), and particle-size characterization. Advanced offerings include predictive materials modeling, peptide characterization, and specialty inorganic, petrochemical, and contaminant identification analyses.
As a cGMP-compliant, DEA Schedule I–V registered and FDA-inspected laboratory, Triclinic Labs provides method development, validation, and release testing, robust intellectual property support, and regulatory guidance to accelerate timelines and mitigate development risks. Their integrated approach ensures clients achieve reproducible, scalable solutions with maximum efficiency and confidence.